ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos625 M563 M617 M579 M608 M588 M2.39 BInvestigación y desarrollo186 M157 M172 M170 M199 M180 M721 MBeneficio operativo548 M899 M921 M890 M643 M794 M3.25 BTotal de ingresos no operativos20 M18 M-4 M13 M12 M20 M41 MGastos por intereses, netos de intereses capitalizados51 M54 M53 M58 M57 M62 M230 MIngresos no operativos, una vez deducidos los gastos por intereses-32 M-39 M-56 M-45 M-37 M-41 M-179 MIngresos/gastos extraordinarios1 M3 M-1 M0-8 M-1 M-10 MBeneficio antes de impuestos732 M810 M902 M887 M798 M758 M3.35 BParticipación en los beneficios———————Impuestos151 M179 M184 M166 M166 M157 M673 MParticipación minoritaria0000000Otros ingresos/gastos después de impuestos17 M2 M4 M4 M-1 M-3 M4 MBeneficio neto antes de actividades interrumpidas581 M631 M718 M721 M632 M601 M2.67 BOperaciones suspendidas———————Beneficio neto581 M631 M718 M721 M632 M601 M2.67 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas581 M631 M718 M721 M603 M601 M2.64 BBeneficio básico por acción1.281.411.611.631.451.426.11Beneficio por acción diluido1.291.411.611.631.441.426.1Número medio de acciones ordinarias454.2 M447.6 M445.1 M442.9 M443.44 M422.1 M—Acciones diluidas454.85 M448 M445.5 M443.2 M443.83 M422.4 M—EBITDA717 M1.02 B1.04 B1.01 B764 M913 M3.73 BEBIT548 M899 M921 M890 M665 M794 M3.27 BCosto de los ingresos707 M622 M649 M683 M712 M641 M2.69 BOtros costes de producción26 M18 M14 M20 M16 M13 M63 MAmortización y depreciación (flujo de caja)123 M119 M123 M124 M121 M119 M487 M
Zoetis Inc. Class A Common Stock
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.